Targovax to present clinical data on its phase I/II clinical trial evaluating TG01 in resected pancreatic cancer at the ASCO Annual Meeting
Oslo, Norway, 6 April 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target treatment-resistant solid tumors, today announces that clinical data from the phase I/II clinical trial evaluating TG01 in resected pancreatic cancer will be presented at the American Society of Clinical Oncology ('ASCO') Annual Meeting 2017 at McCormick Place in Chicago, Illinois, 2-6 June 2017. The abstract title will be released on 20 April and the abstract will be released on 17 May on abstracts.asco.org. Please see